NCT00003954View on ClinicalTrials.gov

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

December 31, 2002

Conditions
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

melphalan

Given IV

PROCEDURE

autologous hematopoietic stem cell transplantation

Undergo autologous bone marrow or PBSCT

PROCEDURE

autologous bone marrow transplantation

Undergo autologous bone marrow or PBSCT

PROCEDURE

peripheral blood stem cell transplantation

Undergo autologous bone marrow or PBSCT

RADIATION

total-body irradiation

Undergo TBI

PROCEDURE

peripheral blood stem cell transplantation

Undergo donor PBSCT

DRUG

cyclosporine

Given IV and PO

DRUG

mycophenolate mofetil

Given PO

BIOLOGICAL

therapeutic allogeneic lymphocytes

Undergo DLI

Trial Locations (4)

10126

University of Torino, Torino

80217

University of Colorado, Denver

91010

City of Hope, Duarte

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00003954 - Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | Biotech Hunter | Biotech Hunter